Related Experiment Video
Updated: Jun 12, 2026
09:54
Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
Published on: November 4, 2018
Therapeutic liver repopulation for phenylketonuria.
1Department of Molecular and Medical Genetics, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Mail code L103, Portland, OR 97239, USA. hardingc@ohsu.edu
Journal of Inherited Metabolic Disease
|May 25, 2010
Summary
Developing new treatments for phenylketonuria (PKU) is crucial due to dietary compliance issues. Liver repopulation with phenylalanine hydroxylase (PAH)-expressing cells shows promise, but requires a method to promote donor cell growth for effective phenylalanine clearance.
Area of Science:
- Biomedical research
- Metabolic disorders
- Hepatology
Background:
- Phenylketonuria (PKU) management is challenged by long-term dietary compliance difficulties.
- Current treatments for PKU are limited, necessitating novel therapeutic strategies.
- Therapeutic liver repopulation using phenylalanine hydroxylase (PAH)-expressing cells is being explored as a potential PKU treatment.
Purpose of the Study:
- To investigate the potential of therapeutic liver repopulation as a novel treatment for phenylketonuria (PKU).
- To identify the critical requirement for a selective growth advantage for donor cells in liver repopulation therapies.
- To explore methods for achieving successful therapeutic liver repopulation in PKU treatment.
Main Methods:
- Examining the requirements for successful therapeutic liver repopulation, including liver regeneration stimuli and selective donor cell growth.
- Evaluating the limitations of current approaches, such as the lack of growth advantage for wild-type PAH+ hepatocytes.
- Considering the potential and challenges of hepatocyte and haematopoietic stem cell transplantation for liver repopulation in PKU.
Main Results:
- Wild-type PAH+ hepatocytes do not possess a growth advantage over PAH- cells, hindering therapeutic liver repopulation.
- Successful correction of hyperphenylalaninemia via liver repopulation has only been achieved in animal models with inherent donor cell selective advantages.
- Haematopoietic stem cell (HSC)-mediated liver repopulation for PKU has not been reported and may be limited by slow kinetics.
Conclusions:
- A method to provide a selective growth advantage for donor cells is essential for the successful clinical application of therapeutic liver repopulation in PKU.
- Achieving even a 10-20% repopulation with wild-type hepatocytes could potentially normalize phenylalanine clearance in individuals with PKU.
- Further research is needed to develop strategies that confer a selective growth advantage for donor cells in liver repopulation therapies for PKU.
Related Concept Videos
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:24Liver Regeneration
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...